Monkeypox vaccine safety and immune response study
Part of Infections clinical trials.
This trial tests a new monkeypox vaccine to see if it is safe and helps the body build protection. It may be an option for adults who were born before 1980 and received a smallpox vaccine, or who meet other health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and born before 1980 with a history of smallpox vaccination
- You have no history of smallpox, monkeypox, or recent close contact with monkeypox
- You are not allergic to eggs, vaccine ingredients, or have had severe allergies before
- You have not used blood products or experimental treatments in the past month or plan to during the trial
- You are not pregnant, breastfeeding, and agree to use birth control for 6 months after vaccination
- You do not have serious chronic, immune, or bleeding conditions, or active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study that follows adults after they get a monkeypox vaccine to learn how their immune system responds. The results may help researchers understand what types of protection the vaccine creates.
This observational study looks at how your body’s defenses work against mpox (monkeypox), based on blood and health information. You may be eligible if you recently got an mpox vaccine or have had mpox infection and are now out of isolation.
This study in West Africa follows people with confirmed mpox (monkeypox) infection and their close contacts to understand how the virus spreads, clears from the body, and how well the mpox vaccine protects people. You may be eligible if you've recently tested positive for mpox, were exposed to someone with mpox, or live in an area offering mpox vaccination.
This study follows people after confirmed mpox, after smallpox vaccination, or in people taking HIV PrEP to learn how the immune system responds over time. It may help scientists better understand protection and immune changes after these exposures.
This study tests how well a booster dose of the MVA-BN mpox vaccine keeps working over time in men who are on or starting PrEP for HIV prevention.
This trial tests a new treatment for mpox (monkeypox) in people with active sores. It aims to see if the treatment helps clear the infection faster and reduce symptoms.
Hear when a new Monkeypox trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.